XOMA 629

Drug Profile

XOMA 629

Alternative Names: 0.1% XMP 629 acetate gel; XMP 629; XMP.629 peptide; XOMA-629

Latest Information Update: 26 Nov 2015

Price : $50

At a glance

  • Originator XOMA
  • Class Antiacnes; Antibacterials; Antifungals
  • Mechanism of Action Endotoxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Bacterial infections; Impetigo
  • Discontinued Acne; Mycoses

Most Recent Events

  • 24 Jul 2008 Phase-II clinical trials in Impetigo in USA (Topical)
  • 14 May 2008 Preclinical trials in Bacterial infections in USA (unspecified route)
  • 07 Sep 2006 XOMA is conducting preclinical optimisation studies of a reformulated topical XOMA 629 product for the treatment of mild-to-moderate acne in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top